All In Biotech

Drug Trial Radar · NCT07791043

A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)

A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment With Efimosfermin Alfa in Adult Participants With Alcohol-related Liver Disease (ALD)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

274

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Aug 11, 2028

Study completion Jan 14, 2030

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in participants with ALD.

Conditions

  • Liver Diseases, Alcoholic

Interventions

  • Efimosfermin alfaDrug

    Efimosfermin alfa will be administered.

  • PlaceboDrug

    Placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in vibration-controlled transient elastography-liver stiffness measurement (VCTE-LSM)Time frame: Baseline (Day 1) and up to Week 60
  2. Change from Baseline in model for end-stage liver disease (MELD) scoreTime frame: Baseline (Day 1) and up to Week 60

Locations

17 sites in 5 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Chandler, Arizona · Recruiting

  • GSK Investigational Site

    Miami Lakes, Florida · Recruiting

  • GSK Investigational Site

    Topeka, Kansas · Recruiting

  • GSK Investigational Site

    Fort Worth, Texas · Recruiting

  • GSK Investigational Site

    San Antonio, Texas · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    CABA, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad AutOnoma de Buenos Aire, Argentina · Recruiting

  • GSK Investigational Site

    Rosario, Argentina · Recruiting

  • GSK Investigational Site

    San Miguel de Tucumán, Argentina · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Athens, Greece · Recruiting

  • GSK Investigational Site

    Athens, Greece · Recruiting

  • GSK Investigational Site

    Daegu, South Korea · Recruiting

  • GSK Investigational Site

    Pusan, South Korea · Recruiting

  • GSK Investigational Site

    Seoul, South Korea · Recruiting

  • GSK Investigational Site

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.